AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34907058
Drug: Weekly self-reported
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly self-reported illness prevalence by sex
Trial: 34907170
Drug: BNT162b2 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 (30 μg, 2 doses, 21 days apart)
Trial: 34907192
Drug: Anti-CCR4 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CCR4 monoclonal antibody mogamulizumab
Trial: 34910393
Drug: Niraparib and
RxNorm normalized name: niraparib and abiraterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib and bevacizumab maintenance therapy
Trial: 34911359
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg once daily for up to 18 months
Trial: 34911463
Drug: REBOA (Resuscitative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REBOA (Resuscitative endovascular balloon occlusion of the aorta) as adjunct treatment to advanced cardiac life support
Trial: 34911667
Drug: Ruxolitinib 5
RxNorm normalized name: ruxolitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg BID, with optional up-titration to a maximum of 15 mg BID
Trial: 34911817
Drug: RP-3500, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP-3500, a novel ATR kinase inhibitor, administered orally.
Trial: 34911956
Drug: Tetrathiomolybdate (TM),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrathiomolybdate (TM), an orally bioavailable copper chelating agent.
Trial: 34911992
Drug: Asunercept 200
RxNorm normalized name: Asunercept
DrugBank: Asunercept (DB15160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunercept 200 mg/week plus standard RT/TMZ (Cohort 1)
Trial: 34911992
Drug: Asunercept 400
RxNorm normalized name: Asunercept
DrugBank: Asunercept (DB15160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asunercept 400 mg/week plus standard RT/TMZ (Cohort 2)
Trial: 34914545
Drug: Mosunetuzumab (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosunetuzumab (group B, step-up dosing)
Trial: 34914826
Drug: Blinatumomab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinatumomab (4 cycles administered every 3 months during the first year after HCT)
Trial: 34915057
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with ritlecitinib and brepocitinib
Trial: 34915574
Drug: belimumab 10
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10 mg/kg intravenous every 28 days for ≤7 years
Trial: 34915909
Drug: Internet-delivered modular
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered modular intervention based on cognitive behavioral therapy (CBT) for 8 weeks
Trial: 34916327
Drug: Perioperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative intravenous S(+)-ketamine plus conventional anaesthesia
Trial: 34917565
Drug: High-dose gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gentamicin regimen
Trial: 34917636
Drug: Implantation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantation of microalgae (photosynthetic cells) for oxygen supply to tissues, specific dosage and duration not mentioned.
Trial: 34918855
Drug: Diabetes treated
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes treated with insulin
Trial: 34919824
Drug: Sotorasib, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotorasib, oral administration once per day
Trial: 34920345
Drug: Neither SXB
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither SXB nor stimulants
Trial: 34920345
Drug: Sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium oxybate (SXB) with or without stimulants
Trial: 34920739
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss with Metformin
Trial: 34921324
Drug: Rapid 5-mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid 5-mL/kg body weight volume expansion
Trial: 34921514
Drug: Romiplostim 1
RxNorm normalized name: ROMIPLOSTIM 125MCG/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romiplostim 1 μg/kg weekly for 2 weeks
Trial: 34921514
Drug: Romiplostim 3
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim 3 μg/kg weekly for 2 weeks
Trial: 34922614
Drug: DBS-based, drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBS-based, drug resistance genotype-informed ART switching algorithm
Trial: 34923853
Drug: Intracoronary autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary autologous CD34+ cell therapy
Trial: 34925553
Drug: DHP107 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP107 (oral paclitaxel) 200 mg/m²
Trial: 34926296
Drug: Tcm self-transfusion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tcm self-transfusion combined with TACE treatment
Trial: 34926296
Drug: TACE treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE treatment alone (control group)
Trial: 34926300
Drug: TACE combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE combined with endoscopic therapy
Trial: 34926386
Drug: Smoking cessation
RxNorm normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cessation treatments
Trial: 34926601
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection
Trial: 34926859
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 110-149 mg/dl
Trial: 34926859
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (n = 72) via continuous intravenous insulin infusion maintaining blood glucose levels of 150-180 mg/dl
Trial: 34927165
Drug: Telehealth physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth physical therapy
Trial: 34927165
Drug: In-person physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person physical therapy
Trial: 34927307
Drug: Earlier locally
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Earlier locally ablative treatment of oligometastases
Trial: 34928709
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 2 doses, followed by computed tomography scan at week 6.
Trial: 34928709
Drug: Nivolumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) for 3rd and 4th doses if no FATE at week 6, followed by Nivolumab monotherapy.
Trial: 34928709
Drug: Nivolumab +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab + Ipilimumab (standard treatment)
Trial: 34930140
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 96 weeks
Trial: 34930140
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg once daily
Trial: 34930194
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy + internet-delivered cognitive behavioral therapy (iCBT)
Trial: 34930194
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy + iCBT in combination with TKA
Trial: 34930194
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment with TKA and usual care physiotherapy
Trial: 34930194
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy + iCBT
Trial: 34930356
Drug: High serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High serum choline concentrations (median 9.51 μg/mL)
Trial: 34930356
Drug: Quartiles 2-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartiles 2-4 (serum choline ≥ 4.00 μg/mL)
Trial: 34930356
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum choline concentrations (median 7.80 μg/mL)
Trial: 34930428
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure lowering (target systolic < 140 mmHg), glycemic control (target 6.1-7.8 mmol/L for non-diabetics and 7.8-10.0 mmol/L for diabetics), anti-pyrexia treatment (target body temperature ≤ 37.5 °C), reversal of anticoagulation (target INR < 1.5 within 1 hour)
Trial: 34930734
Drug: Thoracoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracoscopic surgery with additional treatment after bulla resection (specific details not provided).
Trial: 34930734
Drug: Adverse outcomes
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse outcomes correlated with various treatments (specific details not provided).
Trial: 34930734
Drug: Feasibility of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feasibility of treatment methods (specific details not provided).
Trial: 34930741
Drug: Reperfusion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reperfusion treatment at secondary hospitals
Trial: 34930741
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy at secondary hospitals
Trial: 34930741
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy timing
Trial: 34930741
Drug: In-hospital death
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital death or treatment withdrawal
Trial: 34932001
Drug: New integrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New integrated IT platform for medication reconciliation
Trial: 34932284
Drug: AboBoNT-A (Dysport)
RxNorm normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AboBoNT-A (Dysport) injections, mean doses 909-934 U between cycles 1 and 4
Trial: 34932284
Drug: OnaBoNT-A (Botox)
RxNorm normalized name: botulinum toxin type A Injection [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnaBoNT-A (Botox) injections
Trial: 34932284
Drug: IncoBoNT-A (Xeomin)
RxNorm normalized name: botulinum toxin type A Injection [Xeomin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncoBoNT-A (Xeomin) injections
Trial: 34932394
Drug: Balstilimab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balstilimab (3 mg/kg every 2 weeks) and Zalifrelimab (1 mg/kg every 6 weeks)
Trial: 34932984
Drug: Dual GLP-1/GCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual GLP-1/GCG receptor agonist
Trial: 34933701
Drug: Triclosan 0.5%
RxNorm normalized name: TRICLOSAN 0.5% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triclosan 0.5% followed by 70% alcoholic solution
Trial: 34933824
Drug: CRP measures
RxNorm normalized name: MEASLES VIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP measures collected at antimicrobial treatment start (V1), seven to 10 days later (V2), and two weeks after treatment end (V3).
Trial: 34934447
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment according to hospital protocols
Trial: 34934864
Drug: Nivolumab (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (480 mg intravenously every 4 weeks) + Stereotactic Radiosurgery (SRS)
Trial: 34934987
Drug: Cabergoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.5 mg) twice weekly + placebo daily for 6 months
Trial: 34934987
Drug: Norethindrone acetate
RxNorm normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate (5 mg/day) + placebo twice weekly
Trial: 34935687
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL 4% gelatin intravenous boluses (five sequential boluses)
Trial: 34935687
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL fluid challenge (FC)
Trial: 34935913
Drug: SARS-CoV-2 mRNA
RxNorm normalized name: SARS-CoV-2 mRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 mRNA vaccine (two doses of Pfizer-BioNTech)
Trial: 34936697
Drug: Obinutuzumab plus
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab plus lenalidomide (GALEN combination)
Trial: 35536314
Drug: Elexacaftor/Tezacaftor/Ivacaftor Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elexacaftor/Tezacaftor/Ivacaftor Therapy
Trial: 34937189
Drug: Piperacillin-Tazobactam continuous
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-Tazobactam continuous infusion
Trial: 34937189
Drug: Piperacillin-Tazobactam intermittent
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-Tazobactam intermittent bolus, extended infusion, and continuous infusion methods
Trial: 34937720
Drug: Stratified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified treatment based on prognostic factors
Trial: 34938285
Drug: AS03-adjuvanted H1N1pdm09
RxNorm normalized name: AS03 Adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted H1N1pdm09 vaccine (2009)
Trial: 34938664
Drug: Venetoclax 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 800 mg/day
Trial: 34939008
Drug: HDx therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDx therapy (medium cut-off dialyzer) for 12 weeks after a 2-week baseline observation period of conventional high-flux HD
Trial: 34939008
Drug: HDx therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDx therapy
Trial: 34939013
Drug: Marine n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine n-3 PUFA (2.6 g daily for 44 weeks)
Trial: 34939444
Drug: Yoga practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga practice combined with patient education (PE) for at-home practice, 12 weeks duration, including two 6-week periods: P1 with one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga, P2 with daily autonomous at-home yoga sessions.
Trial: 34939987
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy initiation among AYALWH older than 10 years
Trial: 34941047
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with anlotinib, irinotecan, and vincristine
Trial: 34941067
Drug: Leuprorelin 1.88
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 1.88 to 3.75 mg subcutaneously once every 4 weeks for 96 weeks
Trial: 34941996
Drug: Glofitamab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab (5 µg-25 mg) after single-dose obinutuzumab pretreatment (1000 mg) 7 days prior
Trial: 34941996
Drug: Glofitamab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab (5 µg-25 mg)
Trial: 34942138
Drug: Lower-sodium oxybate
RxNorm normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lower-sodium oxybate (2.5-9.0 g/night)
Trial: 34944886
Drug: Yeast-derived beta
RxNorm normalized name: yeast, beta-D-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast-derived beta glucan (BG) combined with anti-GD2 murine monoclonal antibody 3F8, intravenous 3F8 at a fixed dose of 10 mg/m².
Trial: 34945816
Drug: Pharmacogenomically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomically guided medication treatment
Trial: 34945816
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication treatment
Trial: 34950101
Drug: Drug-Induced Sleep
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Induced Sleep Endoscopy
Trial: 35121899
Drug: BNT162b2 or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 or AZD1222 vaccines (two doses, administered 12 weeks apart)
Trial: 35121899
Drug: BNT162b2 or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 or AZD1222 vaccines
Trial: 34950880
Drug: anti-CD20 treatment
RxNorm normalized name: Allogeneic anti-CD20 CAR T cells
DrugBank: PBCAR20A (DB17189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD20 treatment
Trial: 34951594
Drug: Daily incentives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily incentives for self-weighing (loss incentive)
Trial: 34952881
Drug: Melatonin 4
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 4 mg per os, every night from anaesthesiologist preoperative consultation up to 5 days after surgery.
Trial: 34953337
Drug: Perampanel as
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel as an add-on therapy
Trial: 34953600
Drug: Stereotactic ablative
RxNorm normalized name: ABL
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic ablative body radiotherapy (SABR) followed by pembrolizumab 200 mg administered Q3W for eight cycles
Trial: 34953624
Drug: Gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 250 mg daily and tremelimumab at 3 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Trial: 34953624
Drug: Tremelimumab at
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab at 6 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Trial: 34953624
Drug: Tremelimumab at
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab at 10 mg/kg IV Q4W for 6 cycles followed by Q12W until progression or unacceptable toxicity.
Trial: 34953816
Drug: Anakinra (2-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (2-11 mg/kg/day)
Trial: 34953816
Drug: Anakinra (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (IV dosing every 8-12 hours)
Trial: 34953816
Drug: Anakinra (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (IV therapy during hospitalization)
Trial: 34954052
Drug: SY-007 (1-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-007 (1-60 mg)
Trial: 34954052
Drug: SY-007 (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-007 (10-30 mg)
Trial: 34954341
Drug: Empiric second-line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric second-line treatment (triple therapy with amoxicillin and levofloxacin)
Trial: 34954341
Drug: Moxifloxacin-containing triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-containing triple therapy or levofloxacin-containing quadruple therapy (with bismuth)
Trial: 34954341
Drug: 14-day regimens
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14-day regimens using high doses of proton pump inhibitors with levofloxacin or moxifloxacin
Trial: 34954341
Drug: 3-in-1 single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-in-1 single capsule or levofloxacin-bismuth quadruple therapy
Trial: 34954341
Drug: 14-day quinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day quinolone triple therapies, 14-day levofloxacin-bismuth quadruple therapy, 14-day tetracycline-bismuth classic quadruple therapy, and 10-day bismuth quadruple therapy (as a single capsule)
Trial: 34955443
Drug: Lenalidomide (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (35 mg) administered for 28 days
Trial: 34956230
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride and low-dose IL-2 (HDC/IL-2)